A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma
A Phase 1/1b Dose-Escalation Trial Evaluating CPI-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, in Subjects With Relapsed/Refractory T-Cell Lymphoma
Sponsor: Corvus Pharmaceuticals, Inc.
A PHASE1 clinical study on T-cell Lymphoma, this trial is ongoing. The trial is conducted by Corvus Pharmaceuticals, Inc. and has accumulated 14 data snapshots since 2019. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
14 versions recorded-
Sep 2025 — Present [monthly]
Active Not Recruiting PHASE1
-
May 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE1
-
Sep 2024 — May 2025 [monthly]
Active Not Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1
-
Apr 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
▶ Show 9 earlier versions
-
Jan 2024 — Apr 2024 [monthly]
Recruiting PHASE1
-
Jul 2022 — Jan 2024 [monthly]
Recruiting PHASE1
-
Mar 2022 — Jul 2022 [monthly]
Recruiting PHASE1
-
May 2021 — Mar 2022 [monthly]
Recruiting PHASE1
-
Jan 2021 — May 2021 [monthly]
Recruiting PHASE1
-
May 2020 — Jan 2021 [monthly]
Recruiting PHASE1
-
Feb 2020 — May 2020 [monthly]
Recruiting PHASE1
-
Aug 2019 — Feb 2020 [monthly]
Recruiting PHASE1
-
Jun 2019 — Aug 2019 [monthly]
Recruiting PHASE1
First recorded
May 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Corvus Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .